CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 401–500 of 1,725
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 33
Asoudeh, M., Nguyen, N. A., Raith, M., Denman, D. S., Anozie, U. C., Mokhtarnejad, M., Khomami, B., Skotty, K. M., Isaac, S., Gebhart, T., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.019 · Cited by 34
Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment
Zhou, S., Li, Y., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70 · Cited by 45
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
Tschöpe, C., Elsanhoury, A., & Kristen, A. V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134785 · Cited by 45
“Nex-z was well-tolerated, with infusion-related reactions as the most common adverse events [81].”
InfluentialLiver‐directed drugs for t ransthyretin‐mediated amyloidosis
Brannagan, T. H., Berk, J. L., Gillmore, J. D., Maurer, M. S., Waddington‐Cruz, M., Fontana, M., Masri, A., Obici, L. P., Brambatti, M., Baker, B. F., et al. (2022) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12519 · Cited by 32
“approved or under investigation in the clinic include the antisense oligonucleotides (ASOs) inotersen and eplontersen; the small interfering RNAs (siRNAs) patisiran and vutrisiran; and a CRISPR/Cas9 gene editing tool NTLA-2001 (Table 1; Figure 2).(3,10,31) Due to the role of TTR as a transporter via binding to retinol…”
BackgroundMethodInfluentialSelf-citationUse, exposure and omics characterisation of potential hazard in nanomaterials
Ling, N., Zhang, N., Yong, W. T. L., Misbah, S., Hashim, F., Soon, C. F., Lim, G. P., Peng, W., & Sonne, C. (2023) · Materials Today Advances · doi:10.1016/j.mtadv.2023.100341 · Cited by 32
The potential of gene editing for Huntington’s disease
Duan, W., Urani, E., & Mattson, M. P. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.02.005 · Cited by 33
Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases
Testa, L. C., & Musunuru, K. (2023) · BioDrugs · doi:10.1007/s40259-023-00610-9 · Cited by 39
Tang, D., Yang, Y., Li, Y., Li, Y., Tian, J., Yang, L., Ding, H., Bashir, G., Zhou, H., Ding, Q., et al. (2023) · Theranostics · doi:10.7150/thno.88550 · Cited by 32
“The CRISPR-Cas9 system has demonstrated enormous potential for treating cancer and genetic diseases such as transthyretin amyloidosis [12] , β -hemoglobinopathies [13], nervous system disorders [14], and human immunodeficiency syndrome [15].”
BackgroundChen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 33
Cell therapy for liver disorders: past, present and future
Ortuño‐Costela, M. D. C., Pinzani, M., & Vallier, L. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01050-2 · Cited by 40
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.112724 · Cited by 34
“Encouraging results from preclinical in vitro and in vivo studies have demonstrated favorable safety profiles, justifying progression into human trials [181].”
Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas
Yang, Y.-C., & Yang, H. (2021) · Viruses · doi:10.3390/v14010004 · Cited by 33
“Keywords: hepatitis B virus (HBV); chronic hepatitis B (CHB); HBV cure; CRISPR-Cas9; gene editing”
BackgroundInfluentialRegulatory Considerations for Clinical Trial Applications with CRISPR-Based Medicinal Products
Anliker, B., Childs, L. H., Rau, J., Renner, M., Schüle, S., Schuessler‐Lenz, M., & Sebe, A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0148 · Cited by 35
“14 The medical applicability of CRISPR has expanded, aiming to treat inherited diseases and delving into areas such as immuno-oncology and transplantation.”
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Hong, D., & Iakoucheva, L. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02356-y · Cited by 36
Kotit, S. (2023) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2023.4 · Cited by 56
“…ATTR amyloidosis and polyneuropathy, administration of NTLA-2001 led to decreases in serum TTR protein concentrations through targeted knockout of TTR with only mild adverse events 40 providing clinical proof of concept for in vivo CRISPR-Cas9–mediated gene editing as a therapeutic strategy.”
BackgroundResultInfluentialGene therapy for sickle cell disease
Leonard, A. K., & Tisdale, J. F. (2023) · Hematology · doi:10.1182/hematology.2023000487 · Cited by 37
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 34
“The drug consists of Cas9 protein encoding chemically modified mRNA and single guide RNAs (sgRNAs) targeting hATTR gene encapsulated in lipid nano-particles (LNP) 147 .”
MethodAllemailem, K. S., Almatroudi, A., Rahmani, A. H., Alrumaihi, F., Alradhi, A. E., Al-Subaiyel, A., Algahtani, M., Almousa, R. M., Mahzari, A., Sindi, A. A. A., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455574 · Cited by 40
“208 Furthermore, the elimination of some immune system diseases such as acquired immunodeficiency syndrome (AIDS) is seriously in consideration by different clinical trials involving CRISPR/Cas9 genome editing technology.”
BackgroundLinthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 33
Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications
Liu, X., Gao, M., & Bao, J. (2025) · Nanomaterials · doi:10.3390/nano15070540 · Cited by 34
Peptide-Assisted Nucleic Acid Delivery Systems on the Rise
Tarvirdipour, S., Skowicki, M., Schoenenberger, C., & Palivan, C. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169092 · Cited by 30
“Quite recently, a new treatment involving gene editing CRISPER has made a mark by using mRNA encoding Cas [1,2].”
Imaging-Guided Treatment for Cardiac Amyloidosis
Ioannou, A., Patel, R. K., Gillmore, J. D., & Fontana, M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01703-7 · Cited by 31
Self-citationPoly (beta‐amino ester) as an in vivo nanocarrier for therapeutic nucleic acids
Nezhad, M. S. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28269 · Cited by 31
Gene Therapy Approaches for the Treatment of Hemophilia B
Soroka, A. B., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310766 · Cited by 30
“LNP-CRISPR-Cas9 has been shown to effectively inhibit pathogenic TTR expression by approximately 90%, with mild side effects [49].”
BackgroundWaddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
“49 Recently, Gao et al. 50 and Riley et al. 51 independently demonstrated delivery of mRNA predominantly to the liver after injection of lipid nanoparticles into the mouse fetus by injection into the liver and via the vitelline vessel, respectively.”
MethodGene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 41
Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems
Brezgin, S. A., Kostyusheva, A. P., Олеговна, Б. Е., Volchkova, E. V., Gegechkori, V., Gordeychuk, I. V., Glebe, D., Kostyushev, D. S., & Chulanov, V. (2021) · Viruses · doi:10.3390/v13071373 · Cited by 31
Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells
Simhadri, V. L., Hopkins, L., McGill, J. R., Duke, B. R., Mukherjee, S., Zhang, K., & Sauna, Z. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25414-9 · Cited by 30
Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy
Rosanwo, T. O., & Bauer, D. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.002 · Cited by 35
Obici, L. P., & Mussinelli, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01154-y · Cited by 28
“Besides RNA-targeting agents, sustained lockdown of circulating TTR can be achieved through application of CRISPRCas9-mediated gene editing.”
BackgroundInfluentialRecent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders
Lee, M., Lee, I., & Wang, K. (2022) · Biomedicines · doi:10.3390/biomedicines10010158 · Cited by 28
“All the patients showed decreased serum TTR protein concentrations through the targeted knockout of TTR (NCT04601051) [127].”
BackgroundAntisense therapies in neurological diseases
de Courssou, J.-B. B., Dürr, A., Adams, D., Corvol, J., & Mariani, L. (2021) · Brain · doi:10.1093/brain/awab423 · Cited by 33
CRISPR and cardiovascular diseases
Musunuru, K. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac048 · Cited by 38
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
Chen, X., Guo, R., Zhao, C., Xu, J., Song, H., Yu, H., Pilarsky, C. P., Nainu, F., Li, J., Zhou, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.939090 · Cited by 34
Gertz, M. A. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.005 · Cited by 34
Liang, J., Jin, X., Deng, X., Huang, Q., Zhang, S., Chen, W., & Zhang, X. (2024) · Materials Today · doi:10.1016/j.mattod.2024.07.004 · Cited by 32
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
“138 However, recent in-human observations 89,115 indicate a potential for systemic persistence of LNP particles and their cargo over several days post-infusion, presenting a concern for class I and II mediated immunogenicity.”
InfluentialSelf-splicing RNA circularization facilitated by intact group I and II introns
Shen, Y. H., Li, B., Dong, L., Tang, W., Ren, J., Chen, F., Zheng, W., Yu, Y. F., Gao, L., & Wei, W. (2025) · Nature Communications · doi:10.1038/s41467-025-62607-y · Cited by 31
Engineering challenges and translational opportunities in emerging gene delivery platforms
Ma, Y., Dong, S., Wu, A., Jeong, S. D., Lee, A. S., Jiang, W., & Kim, B. Y. S. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01643-5 · Cited by 49
“In metabolic disorders, NTLA-2001 achieved up to 96% transthyretin protein reduction after a single infusion in patients with transthyretin amyloidosis 220 .”
Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing
Chae, S.-Y., Jeong, E., Kang, S., Yim, Y., Kim, J., & Min, D. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.035 · Cited by 28
Sousa, D. A., Gaspar, R., Ferreira, C. J. O., Baltazar, F., Rodrigues, L. R., & Silva, B. F. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051087 · Cited by 27
“In a landmark recent result, an early-stage clinical trial has shown that ionizable lipid nanoparticles encapsulating mRNA-encoded Cas9 and sgRNA targeting the transthyretin amyloidosis gene led to a marked decrease of the misfolded protein in blood, opening excellent prospects for future treatments [47].”
BackgroundShoop, W. K., Bacman, S. R., Barrera-Paez, J. D., & Moraes, C. T. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00200-7 · Cited by 33
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
Torella, L., Klermund, J., Bilbao‐Arribas, M., Tamayo, I., Andrieux, G., Chmielewski, K. O., Vales, Á., Olagüe, C., Moreno, D., Raimondi, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00008-8 · Cited by 31
“Recently, this strategy was clinically tested in patients with transthyretin amyloidosis (ATTR) using lipid nanoparticles (LNP) containing a CRISPR-Cas9 system targeting the aberrant transthyretin (TTR) in the liver.”
InfluentialKitzler, T. M., & Chun, J. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231154185 · Cited by 35
Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing
Rostami, N., Gomari, M. M., Choupani, E., Abkhiz, S., Fadaie, M., Eslami, S. S., Mahmoudi, Z., Zhang, Y., Puri, M., Monfared, F. N., et al. (2024) · Small Science · doi:10.1002/smsc.202400192 · Cited by 31
Jiang, Y., Chen, S., Hsiao, S., Zhang, H., Xie, D., Wang, Z. J., Ren, W., Liu, M., Liao, J., & Wu, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.003 · Cited by 33
Ge, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 29
Epigenetic editing: from concept to clinic
Heller, E. A., Bintu, L., & Rots, M. G. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01323-0 · Cited by 42
Approaches to Enhance Precise CRISPR/Cas9-Mediated Genome Editing
Denes, C. E., Cole, A. J., Aksoy, Y. A., Li, G., Neely, G. G., & Hesselson, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168571 · Cited by 32
“Sci. 2021, 22, 8571 13 of 18 Abbreviations ABE, adenine base editor; AID, activation-induced cytosine deaminase; ATR, Ataxiatelangiectasia mutated and Rad3-related kinase; BE, base editor; bp, base pair; CAR, chimeric antigen receptor; Cas9, CRISPR-associated protein; CBE, cytosine base editor; CGBE1, C→G base editor…”
BackgroundInfluentialDohrn, M. F., Medina, J., Dague, K. O., & Hund, E. (2021) · Neurological Research and Practice · doi:10.1186/s42466-021-00155-8 · Cited by 27
“3 mg/kg) experiencing an over 80% reduction 28 days after infusion [63].”
BackgroundNygaard, G., Szigetvari, P. D., Grindheim, A. K., Ruoff, P., Martínez, A., Haavik, J., Kleppe, R., & Flydal, M. I. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111186 · Cited by 30
Houghton, B. C., Panchal, N., Haas, S. A., Chmielewski, K. O., Hildenbeutel, M., Whittaker, T. E., Mussolino, C., Cathomen, T., Thrasher, A. J., & Booth, C. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.828489 · Cited by 28
“All these platforms have entered the clinic, and the data from these trials is building an understanding of their safety profile and clinical efficacy (Tebas et al., 2014; Qasim et al., 2017; Frangoul et al., 2020; Stadtmauer et al., 2020; Gillmore et al., 2021).”
BackgroundCRISPR/Cas9 in the era of nanomedicine and synthetic biology
Schmidt, T. J. N., Berarducci, B., Konstantinidou, S., & Raffa, V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103375 · Cited by 29
Quarta, C. C., Fontana, M., Damy, T., Catini, J., Simoneau, D., Mercuri, M. F., García‐Pavía, P., Maurer, M. S., & Palladini, G. O. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1073503 · Cited by 27
Self-citationSofias, A. M., & Lammers, T. (2023) · Nature Nanotechnology · doi:10.1038/s41565-022-01265-3 · Cited by 28
Kwon, J., Kim, M., Hwang, W., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H., Eom, J.-H., et al. (2023) · Genome biology · doi:10.1186/s13059-022-02842-4 · Cited by 24
“In a recent study performed by Intellia, GUIDE-seq, SITEseq, and Cas-OFFinder were used to identify potential off-target sites for the investigational therapy NTLA-2001 [22].”
MethodInfluentialEngineering Cas9: next generation of genomic editors
Kovalev, M. A., Davletshin, A. I., & Karpov, D. S. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13056-y · Cited by 32
“According to some authors, immuno-suppression can help in vivo (Gillmore et al. 2021), while in other works immunosuppression as well as the use of tissue-specific promoters are ineffective (Hakim et al. 2021).”
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
Leandro, K., Rufino‐Ramos, D., Breyne, K., Ianni, E. D., Lopes, S., Nobre, R. J., Kleinstiver, B. P., Perdigão, P. R. L., Breakefield, X. O., & de Almeida, L. P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115346 · Cited by 28
Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects
Clerc, O. F., Vijayakumar, S., & Dorbala, S. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.05.012 · Cited by 26
Girard, A. A., & Sperry, B. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10444-4 · Cited by 30
“Phase 1 data suggests 90–95% TTR protein reduction with a single drug infusion [6].”
Sekijima, Y., & Sousa, L. (2024) · Amyloid · doi:10.1080/13506129.2024.2435573 · Cited by 25
“In addition, microbleeds, superficial siderosis, and convex subarachnoid haemorrhages similar to Aβ-type CAA can be seen on MRI in patients with CNS ATTR amyloidosis [19,25,56,62,76,88,89].”
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 30
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 57
“This approach has thus progressed to phase III clinical trials 217 .”
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Wan, P., Tang, S., Lin, D., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., et al. (2025) · Nature Medicine · doi:10.1016/j.atherosclerosis.2025.119507 · Cited by 47
Urnov, F. D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.019 · Cited by 26
“29 No 11 Novem safe harbor” platform enabling trials both in hemophilia and lysosomal storage diseases (change of transgene(11)), and a “nonviral delivery of CRISPR/Cas to the liver” platform enabling trials in TTR amyloidosis and hereditary angioedema (change of gRNA).(4)”
BackgroundAdvancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 31
Delbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 28
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 28
Gene-Targeted DNA Methylation: Towards Long-Lasting Reprogramming of Gene Expression?
Cortés-Mancera, F., Sarno, F., Goubert, D., & Rots, M. G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_18 · Cited by 26
Razvi, Y., Porcari, A., di Nora, C., Patel, R., Ioannou, A., Rauf, M., Masi, A., Law, S., Chacko, L., Rezk, T., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1075806 · Cited by 25
“Examples include TTR specific RNA interference or antisense oligonucleotide therapies such as patisiran and inotersen, TTR stabilizers such as tafamidis and acoramidis (4–6), and the CRISPR/Cas9 based gene-editing therapy NTLA-2001 (7).”
BackgroundSelf-citationBiomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy
Qiao, L., Gao, M., Yi, X., Peng, H., Zhang, R., Yao, W., Sun, G., & He, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.020 · Cited by 27
Gene editing innovations and their applications in cardiomyopathy research
Kyriakopoulou, E., Monnikhof, T., & van Rooij, E. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050088 · Cited by 29
Immunomodulation of the donor lung with CRISPR-mediated activation of IL-10 expression
Mesaki, K., Juvet, S., Yeung, J. C., Guan, Z., Wilson, G. W., Hu, J., Davidson, A. R., Kleinstiver, B. P., Cypel, M., Liu, M., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.06.001 · Cited by 31
Design of red-emitting 1D zinc coordination polymer for targeted drug delivery to nucleus
Xiang, S., Liu, J., Han, G., Zhang, W., Long, Y., Deng, Y., Wang, B., & Weng, Q. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.144177 · Cited by 26
Gardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 25
In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
Lee, J. H., & Han, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00705-1 · Cited by 25
“Each trial was an FDA phase 1 and phase 1/2 clinical trial [78, 86, 87].”
MethodEsposito, F., Dell’Aquila, F., Rhiel, M., Auricchio, S., Chmielewski, K. O., Andrieux, G., Ferla, R., Horrach, P. S., Padmanabhan, A., Cunto, R. D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101619 · Cited by 32
Lipid nanoparticles deliver mRNA to the blood–brain barrier
Kuzminich, Y., Shakked, A., Calkins, R., Rudden, S., Jones, C., Doan, J., Jang, B., Echeverri, E. S., Zenhausern, R., Lian, L., et al. (2024) · Nano Research · doi:10.1007/s12274-024-6827-7 · Cited by 26
RNA-based therapies in liver metabolic diseases
Fontanellas, A., Berraondo, P., Urigo, F., Jericó, D., Martini, P. G. V., Pastor, F., & Avila, M. A. (2025) · Gut · doi:10.1136/gutjnl-2023-331742 · Cited by 33
Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 33
“LNPs have made significant progress in cell and animal models with genomic abnormalities by delivering gene editing tools for various applications, including CRISPR/ Cas9 for gene knockout, and CRISPR/Cas/ssDNA as well as base editors for precise gene correction [141, 143, 144, 157, 158].”
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
“Current systemic RNA datasets suggest that NHPs can model humans 1,4,55,56 , but it is possible that NHPs will not always recapitulate delivery in patients.”
CRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 26
The Basis and Promise of Programmable RNA Editing and Modification
Lo, N., Xu, X., Soares, F., & He, H. H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.834413 · Cited by 25
Basic Principles and Clinical Applications of CRISPR-Based Genome Editing
Lim, J. M., & Kim, S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.2.105 · Cited by 28
Integrating CRISPR/Cas systems with programmable DNA nanostructures for delivery and beyond
Piskunen, P., Latham, R., West, C. E., Castronovo, M., & Linko, V. (2022) · iScience · doi:10.1016/j.isci.2022.104389 · Cited by 26
Yan, Z., Vorhies, K., Feng, Z., Park, S. Y., Choi, S. H., Zhang, Y., Winter, M. C., Sun, X., & Engelhardt, J. F. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.036 · Cited by 26
“22 Gene editing theoretically solves the complexities of CFTR regulation at the cellular level in the lung.”
Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy
Maurer, M. S. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.014 · Cited by 25
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
Giovannelli, I., Higginbottom, A., Kirby, J., Azzouz, M., & Shaw, P. J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00751-5 · Cited by 25
Morfino, P., Aimo, A., Vergaro, G., Sanguinetti, C., Castiglione, V., Franzini, M., Perrone, M. A., & Emdin, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041129 · Cited by 23
Lipo-Xenopeptide Polyplexes for CRISPR/Cas9 based Gene editing at ultra-low dose
Germer, J., Lessl, A.-L., Pöhmerer, J., Grau, M., Weidinger, E., Höhn, M., Yazdi, M., Cappelluti, M. A., Lombardo, A., Lächelt, U., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.037 · Cited by 27
“S1 ) and literature precedents [43,70], with the rational that the sgRNA needs to persist in the cytoplasm until Cas9 protein is translated and the RNP is assembled.”
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Barazandeh, S., Özden, F., Hınçer, A., Şeker, U. Ö. Ş., & Çiçek, A. E. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf134 · Cited by 35
“A phase 1 study addressing transthyretin amyloidosis utilized a dosage of 0.3mg/kg to patients, resulting in the expression of Cas9 and the delivery of its single guide RNA to knock out the transthyre-tin gene, representing a potential treatment for this disease (Gillmore et al. 2021).”
CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer’s Disease
Raffaele, I., Cipriano, G. L., Anchesi, I., Oddo, S., & Silvestro, S. (2025) · Antioxidants · doi:10.3390/antiox14070781 · Cited by 34
“Phase 1 results demonstrated a good safety profile, with mild and transient adverse events highlighting the feasibility of in vivo gene editing in humans [54,55].”
Gong, N., Kim, D., Alameh, M., El-Mayta, R. D., Han, E. L., Dwivedi, G., Palanki, R., Shi, Q., Han, X., Xue, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01422-8 · Cited by 44
“30 and 31).”
In vivo engineering of CAR-T cells: delivery strategies and clinical translation
Gao, Y., Hu, J., An, N., Wen, X., & Li, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00899-y · Cited by 29
“Notably, NTLA-2001—a systemically administered CRISPR–Cas9 LNP platform for transthyretin amyloidosis—has demonstrated durable in vivo gene editing with favorable safety profiles in human studies [146].”
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 25
Lyu, P., & Lu, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158750 · Cited by 26
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



